Hahn, Ph.D., Executive Chairman of Accu-Break Pharmaceuticals, Inc. ‘Jointly, we are looking forward to filing the first of what we anticipate will be many 505 New Drug Applications for items utilizing our patented Accu-Break technologies in conjunction with Alembic’s broad bottom of active pharmaceutical elements and formulations.’.. ABP, Alembic enter license and development contract for Accu-Break tablet systems Accu-Break Pharmaceuticals, Inc. ABP’s patented Accu-Break tablets could be split easily by hand into exact smaller doses to supply maximum flexibility, and to make it easier and safer for sufferers and caregivers to regulate their dosage.S.S.Today, emerging markets represent more than 20 % of Abbott’s total business,’ stated Mr. Light. ‘With this deal, the combined Healthcare Abbott and Solutions businesses can be the clear market head in India, with a market share of approximately 7 %,’ said Ajay Piramal, chairman, Piramal Group. ‘This was our collective vision and I am glad that those who find themselves part of Piramal’s Healthcare Solutions business will realize this dream.’ The Indian Pharmaceutical Market India is among the world’s fastest-developing pharmaceutical marketplaces, due in large part to branded generics. The market will generate almost $8 billion in pharmaceutical annual sales this year, a number that is expected to a lot more than double by 2015. Abbott estimates the growth of its Indian pharmaceutical business with Piramal to approach 20 % each year, with expected sales of more than $2.5 billion by 2020.